Evolution of Thromboelastography During Tranexamic Acid Treatment

Inclusion Criteria:

* Patient affiliated to a social security regimen or beneficiary of the same
* Signed written informed consent form
* Confirmed diagnosis of a hematological malignancy and undergoing intensive chemotherapy
* Expected to experience hypoproliferative thrombocytopenia resulting in a platelet count of ≤10 G/L for ≥ 5 days

Exclusion Criteria:

* Pregnant women
* Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
* Refractoriness to platelet transfusion or requirement for a specific type of platelet transfusion (ABO-compatible, plasma-free)
* Ongoing anticoagulant therapy or antiplatelet therapy at the time of enrolment
* Treatment with any pro-coagulant agent within 48 hours of enrolment, or enrolment in other trials involving platelet transfusions, platelet growth factors, or presentation of a known hypercoagulable state
* Diagnosis of arterial or venous thromboembolic disease within the previous year
* Patient experiencing a bleeding event WHO grade ≥ 2 within 7 days before inclusion
* contra-indications to tranexamic acid (allergy, history of seizures, creatinine clearance \< 30 mL/min)
* Refusing participation